Psoriasis

Deucravacitinib demonstrated superiority compared with placebo and apremilast in the treatment of adults with moderate to severe plaque psoriasis, according to findings from a phase 3 trial.

An unmet need exists to treat generalized pustular psoriasis and its flares, leading many patients to seek emergency or inpatient treatment, according to a study.

Arcutis has announced positive topline results from the ARRECTOR pivotal phase 3 trial evaluating roflumilast foam 0.3% for the treatment of adults and adolescents with scalp and body psoriasis, according to a company press release.

Patients with psoriasis taking apremilast saw a 5% to 6% decrease in subcutaneous and visceral adiposity, indicating that the drug may benefit cardiometabolic health, according to a study.

Psoriasis is not only a disease that impacts patients physically, with scars and red patchy skin, but it also impacts patients emotionally. Patients’ mental health often suffer due to the anxieties of living with the condition.

MILAN — Patients with psoriasis who initially responded to bimekizumab maintained that response through 3 years with maintenance dosing, according to an open label long-term extension trial

Psoriasis is not only a disease that impacts patients physically, with scars and red patchy skin, but it also impacts patients emotionally. Patients’ mental health often suffer due to the anxieties of living with the condition.

Although psoriasis therapies continue to expand and improve, patients with skin of color still face barriers in access to care and diagnosis, especially if physicians are not adequately trained to identify the condition in all skin types.

MILAN — Clinical efficacy was maintained with long-term use of deucravacitinib in plaque psoriasis, according to study results presented at the European Academy of Dermatology and Venereology Congress.

The burden of psoriasis in people with skin of color is significant and there are many challenges in this patient population that need to be addressed.